AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of AnaptysBio stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $51.00, for a total transaction of $510,000.00. Following the sale, the insider directly owned 8,947 shares of the company’s stock, valued at $456,297. This represents a 52.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.29 during trading hours on Tuesday, reaching $50.04. The company had a trading volume of 406,939 shares, compared to its average volume of 692,903. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $51.43. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -17.74 and a beta of 0.28. The company has a 50 day moving average of $39.15 and a 200 day moving average of $29.22.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a share repurchase plan on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of the company. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares in the last quarter. Bessemer Group Inc. boosted its holdings in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter. Osaic Holdings Inc. grew its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, Covestor Ltd increased its stake in AnaptysBio by 131,540.0% in the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 6,577 shares during the last quarter.

Analysts Set New Price Targets

ANAB has been the topic of several analyst reports. HC Wainwright cut their target price on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their price objective on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and an average target price of $55.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.